KCT0006994尚未招募未知
Efficacy and Safety of Yukmijihwang-tang in the Treatment of Cough-Variant Asthma: Study Protocol for a Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Trial
Daejeon Korean Medicine Hospital of Daejeon University0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19?(Year) 至 65?(Year)（—）
- 性别
- All
入选标准
- •1. Men and women aged 19 ~ 65 years
- •2. Those diagnosed with cough-variant asthma (CVA) by satisfying the following criteria
- •- chronic cough for more than 8 weeks
- •- no history of wheezing or dyspnea
- •- normal FEV1 and FVC (higher than 80% predicted, each)
- •- airway hyperresponsiveness with a positive bronchial provocation test (Methacholine PC20 <8mg or Mannitol PC15 <635mg)
- •- no abnormal chest radiographic findings that could be responsible for the cough
- •3. Those who voluntarily agreed to participate in this clinical study in written form
排除标准
- •1. Those with other causes of chronic cough (ex. chronic sinusitis, allergic rhinitis, gastroesophageal reflux disease, and drug-induced cough)
- •2. Those who have taken the following medications
- •- Immunosuppressants or immunomodulators
- •- within 2 weeks of screening: theophylline
- •- within 4 weeks of screening: systemic (oral or injection) and topical (inhaled or nasal spray) corticosteroids, leukotriene receptor antagonists, antihistamines, other anti-allergic drugs
- •- within 12 weeks of screening: anti-IgE antibody, allergen immunotherapy
- •3. Current smokers (or stop smoking for less than 6 months from screening date)
- •4. Those who used an asthma treatment other than concomitant medication(Ciclesonide 80µg) and rescue medication(salbutamol sulphate)
- •5. One or more of the following typical asthma exacerbations during the run-in period
- •- requires prescription of systemic corticosteroids for at least 3 days
- •- requires hospitalization for systemic corticosteroid administration due to asthma exacerbation
- •- requires emergency room visit for systemic corticosteroid administration due to asthma exacerbation
- •6. Respiratory infection (upper and lower respiratory tract) at a level that requires a change of the asthma treatment stage during the run-in period
- •7. Those with severe respiratory disease other than asthma (chronic obstructive pulmonary disease, cystic fibrosis, pneumonia, interstitial lung disease, tuberculosis and latent tuberculosis, lung cancer, laryngeal cancer, nasopharyngeal cancer, asthma other than cough-type asthma, etc)
- •8. Those with clinically significant disorders of the liver, kidney, cardiovascular system, respiratory system, endocrine system, and central nervous system on physical examination and clinical examination or with history of malignant tumors or psychiatric system(However, possible if there is no recurrence for more than 5 years after surgery)
- •9. Abnormal liver or renal function (ALT, AST, ALP, creatinine values = 2 times the upper limit of normal)
- •10. Hepatitis A (active) or hepatitis B (active) or hepatitis C
- •11. History of hypersensitivity reaction to the investigational product
- •12. Genetic disorders, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •13. History of excessive alcohol use or drug addiction
- •14. Pregnant or lactating women
- •15. Those who do not use a medically acceptable contraceptive method during the clinical trial period and after 30 days for women and 100 days for men after the last administration of the investigational drug
- •? Medically acceptable contraceptive method
- •- use of an intrauterine device with a proven rate of pregnancy failure in the spouse (or partner)
- •- simultaneous use of barrier contraceptive methods (for men or women) and spermicide
- •- surgery of yourself or your partner (vasectomy, tubectomy/tubal ligation, hysterectomy)
- •16. Experience of participating in a different clinical study within 30 days prior to participation in this clinical study
- •17. Those who were determined to be ineligible to participate in this study
研究者
相似试验
招募中
不适用
Efficacy and safety of Yukmijihwang-tang in patients with type 2 diabetes who have microalbuminuria- a pilot studyEndocrine, nutritional and metabolic diseaseKCT0001853Daegu Catholic University Medical Center30
招募中
不适用
Efficacy and safety of Yukmijihwang-tang added to insulin-metformin therapy in patients with type 2 diabetes -a pilot studyEndocrine, nutritional and metabolic diseaseKCT0001402Daegu Catholic Univercity Medical Center14
已完成
不适用
Efficacy and safety of Yijin-tang on polycystic ovarian syndrome: A single-arm pilot studyEndocrine, nutritional and metabolic diseaseKCT0002749Kyung Hee University Oriental Medicine Hospital at Gangdong15
招募中
不适用
The Efficacy and safety of Hwangryunhaedok-tang on Hangover and study of changes in gut microbiota compositioKCT0003683Pusan National University Korean Medicine Hospital40
已完成
不适用
Safety and efficacy of Bojungikki-tang in advanced NSCLC patients receiving treatment with immune checkpoint inhibitors: A study protocol for a multicenter, double-blind, randomized, placebo-controlled pilot trialNeoplasmsKCT0006689Koera University Guro Hospital30